Breaking News

GenScript & Avectas Partner to Develop Improved Non-Viral Cell Therapy Manufacturing Process

Aim to demonstrate a novel and efficient solution for cell therapy manufacturing and to improve editing efficiency and cell viability.

Author Image

By: Charlie Sternberg

Associate Editor

GenScript USA Inc., the world’s leading life-science research tools and services provider and Avectas, a cell engineering technology leader, are partnering to develop an improved non-viral cell therapy manufacturing process.   By combining Avectas’ cell engineering technology and know-how with GenScript’s expertise in synthetic long oligo production, the partnership aims to demonstrate a novel and efficient solution for cell therapy manufacturing and to improve editing effici...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters